)
IN NASAL CONGESTION
AS EARLY AS DAY 21,a
Post hoc analysis. Results are descriptive. Definitive conclusions cannot be made.1
aLSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.13, -0.01).1,2
in NC score through
Week 523,b,c
bNC score at Week 24 in SINUS-52 (coprimary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -0.87 (95% CI: -1.03, -0.71) (-1.25 from a baseline score of 2.46 vs -0.38 from a baseline score of 2.38, respectively) (P<0.0001).3,4
cNC score at Week 52 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -0.98 (95% CI: -1.17, -0.79) (-1.35 from a baseline score of 2.48 vs -0.37 from a baseline score of 2.38, respectively) (P<0.0001).3,4
dNC score at Week 24 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -0.79 (95% CI: -0.98, -0.61) (-1.17 from a baseline score of 2.48 vs -0.38 from a baseline score of 2.38, respectively).3
Nasal congestion/obstruction (NC) score (range 0-3); reduced score indicates improvement.4
INCS, intranasal corticosteroids; LSM, least squares mean; Q2W, once every 2 weeks.
Illustrations of endoscopy adapted from actual patient images. Individual results may vary.
Reduction in bilateral
NPS as early as Week 4,g sustained through
Week 523,e,f
eNPS at Week 52 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -2.40 (95% CI: -2.77, -2.02) (-2.24 from a baseline score of 6.07 vs 0.15 from a baseline score of 5.96, respectively) (P<0.0001).3,4
fNPS at Week 24 in SINUS-52 (coprimary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -1.80 (95% CI: -2.10, -1.51) (-1.71 from a baseline score of 6.18 vs 0.10 from a baseline score of 5.96, respectively) (P<0.0001).3,4
gNPS at Week 4 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -1.18 (95% CI: -1.47, -0.90) (-1.13 from a baseline score of 6.07 vs 0.05 from a baseline score of 5.96, respectively).3
hNPS at Week 24 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -1.79 (95% CI: -2.13, -1.44) (-1.69 from a baseline score of 6.07 vs 0.09 from a baseline score of 5.96, respectively).3
Nasal polyp score (NPS), the sum of right and left nostril scores (range 0-4 for each nostril, range 0-8 in total) as evaluated by nasal endoscopy: reduced score indicates improvement.4
INCS, intranasal corticosteroids; LSM, least squares mean; Q2W, once every 2 weeks.
CRSwNP, chronic rhinosinusitis with nasal polyps.
Use of DUPIXENT for the CRSwNP indication in patients aged 12-17 years is supported by evidence from studies of DUPIXENT as add-on maintenance
treatment in adults with inadequately controlled CRSwNP.4